Paper - WANFANG MED ONLINE

You Position: Home > Paper

Research progress of new antimicrobial agents for drug-resistant pathogenic bacteria

( views:85, downloads:7 )

Author:: No author available

Journal Title:: Chinese Journal of Clinical Infectious Diseases

Issue:: 4

DOI:: 10.3760/cma.j.issn.1674-2397.2021.04.002

Key Word:: 抗菌药物;细菌耐药;β-内酰胺酶;噁唑烷酮类抗菌药物;糖肽类抗生素;喹诺酮类抗菌药物;抗真菌药物;Anti-bacterial agents;Bacterial resistance;β-lactamase;Oxazolidinones;Glycopeptide antibiotics;Quinolone antibacterial drugs;Antifungal drugs

Abstract： This article reviews the status quo of new antimicrobial agents that have been approved or undergoing phase Ⅱ/Ⅲ clinical trials in last five years at home and abroad, including new β-lactamase inhibitors and their compound preparations, oxazolidinones, tetracyclines, aminoglycosides, glycopeptides, quinolones, new antifungal agents, cyclic lipopeptides and new anti-mycobacterial agents. The antibacterial activities, main mechanisms of drug resistance, and progress of clinical studies of 27 new drugs were introduced to provide a reference for their clinical application.

Reference

[1]戴俊,凌静,郭文.氨基糖苷类抗生素的发展现状与机遇[J].2019,(11).
[2]黄志伟.Vabomere药品说明书[J].2019,(2).
[3]石宇星,赵烨,刘相奎.新型全合成四环素类抗生素eravacycline[J].2020,(2).
[4]刘利利,张继瑜.噁唑烷酮-喹诺酮杂合物的研究进展[J].2018,(1).
[5]谢新宇.新型抗真菌药阿尼芬净的研究进展[J].2011,(5).
[6]刘鑫荣.加雷沙星的临床研究[J].2011,(4).
[7]李岷,沈永年,吕桂霞,等.棘白菌素类抗真菌药[J].2009,(4).
[8]肖婷婷,肖永红.耐碳青霉烯类肠杆菌科细菌感染治疗策略研究进展[J].2018,(1).
[9]史丽娟,石磊.新型抗革兰阳性菌药物--达托霉素[J].2008,(7).
[10]覃尚忠.达托霉素研究进展[J].2006,(6).
[11]宋婷婷,冯婧劼,马荣.抗真菌药物艾沙康唑研究进展[J].2015,(3).
[12]彭希希,王赛赛,付琛,等.新型环脂肽抗生素达托霉素研究进展[J].2018,(6).
[13]David H,Salinger,Vishak,Subramoney,Daniel,Everitt,etc.Population Pharmacokinetics of the Antituberculosis Agent Pretomanid.[J].2019,63(10).
[14].Correction: Simultaneous administration of imipenem/cilastatin/relebactam with selected intravenous antimicrobials, a stewardship approach.[J].2020,15(6).
[15]闫江坤.Imipenem/Cilastatin/Relebactam (Recarbrio)[J].2020,(3).
[16]Kaewpoowat, Quanhathai,Ostrosky-Zeichner, Luis.Tigecycline: a critical safety review[J].2015,14(2).
[17].抗结核新药贝达喹啉临床应用专家共识（2020年更新版）[J].2021,(2).
[18]O'Riordan, William,Green, Sinikka,Overcash, J. Scott,etc.Omadacycline for Acute Bacterial Skin and Skin-Structure Infections[J].2019,380(6).
[19]Wallis, Robert S.,Dawson, Rodney,Friedrich, Sven O.,etc.Mycobactericidal Activity of Sutezolid (PNU-100480) in Sputum (EBA) and Blood (WBA) of Patients with Pulmonary Tuberculosis.[J].2014,9(4).
[20]Munita, Jose M.,Aitken, Samuel L.,Miller, William R.,etc.Multicenter Evaluation of Ceftolozane/Tazobactam for Serious Infections Caused by Carbapenem-Resistant Pseudomonas aeruginosa[J].2017,65(1).
[21]Quan, Jingjing,Li, Xi,Chen, Yan,etc.Prevalence of mcr-1 in Escherichia coli and Klebsiella pneumoniae recovered from bloodstream infections in China: a multicentre longitudinal study[J].2017,17(4).
[22]Mangani, Stefano,Docquier, Jean-Denis.An update on beta-lactamase inhibitor discovery and development[J].2018,36.
[23]Chambers,H.F..Pharmacology and the treatment of complicated skin and skin-structure infections[J].2014,370(23).
[24]Sader, Helio S.,Rhomberg, Paul R.,Flamm, Robert K.,etc.WCK 5222 (cefepime/zidebactam) antimicrobial activity tested against Gram-negative organisms producing clinically relevant β-lactamases[J].2017,72(6).
[25]Bai, Xiang-Rong,Yan, Su-Ying,Liu, Jia-Ming,etc.Efficacy and safety of tigecycline monotherapy versus combination therapy for the treatment of hospital-acquired pneumonia (HAP): a meta-analysis of cohort studies[J].2018,30(3).
[26]Plast Verarbeiter Group.Erfolgsfaktor Information[J].2008,59(9).
[27]M R, Barbachyn,D K, Hutchinson,S J, Brickner,etc.Identification of a novel oxazolidinone (U-100480) with potent antimycobacterial activity.[J].1996,39(3).
[28].Antimicrobial Activity of Murepavadin Tested against Clinical Isolates of Pseudomonas aeruginosa from the United States, Europe, and China.[J].2018,(Spec).
[29].In vitro and in vivo activity of contezolid (MRX-I) against Mycobacterium tuberculosis.[J].2018,(Spec).
[30]George G. Zhanel,Phillip Chung,Heather Adam,etc.Ceftolozane\/Tazobactam: A Novel Cephalosporin\/\u03b2-Lactamase Inhibitor Combination with Activity Against Multidrug-Resistant Gram-Negative Bacilli[J].2013,74(1).
[31]李双,王琳,杨君义,等.抗耐甲氧西林金黄色葡萄球菌的新型氟喹诺酮类药物德拉沙星[J].2018,(19).
[32]Bin,Liu,Robert E Lee,Trout,Guo-Hua,Chu,etc.Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo-β-lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections.[J].2020,63(6).
[33]Patientia,R.F.,Lounis,N.,Narasimooloo,R.,etc.Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: Long-term outcome, tolerability, and effect on emergence of drug resistance[J].2012,56(6).
[34]Claire Roger,Jason A. Roberts,Laurent Muller.Clinical Pharmacokinetics and Pharmacodynamics of Oxazolidinones[J].2018,57(5).
[35].β-内酰胺类抗生素/β-内酰胺酶抑制剂复方制剂临床应用专家共识（2020年版）[J].2020,(10).
[36]Wallis,Robert S..Rapid Evaluation in Whole Blood Culture of Regimens for XDR-TB Containing PNU-100480 (Sutezolid), TMC207, PA- 824, SQ109, and Pyrazinamide.[J].2012,7(1).
[37]Kim, Tae Sung,Choe, Jin Ho,Kim, Young Jae,etc.Activity of LCB01-0371, a Novel Oxazolidinone, against Mycobacterium abscessus[J].2017,61(9).
[38]Zhu,T.,Friedrich,S.O.,Diacon,A.,etc.Population pharmacokinetic/pharmacodynamic analysis of the bactericidal activities of sutezolid (pnu-100480) and its major metabolite against intracellular mycobacterium tuberculosis in ex vivo whole-blood cultures of patients with pulmonary tuberculosis[J].2014,58(6).
[39]Wagenlehner, Florian M. E.,Cloutier, Daniel J.,Komirenko, Allison S.,etc.Once-Daily Plazomicin for Complicated Urinary Tract Infections[J].2019,380(8).
[40]Karen Bush,Patricia A. Bradford.Interplay between β-lactamases and new β-lactamase inhibitors[J].2019,17(5).
[41]Wu, Junzhen,Wu, Hailan,Wang, Yu,etc.Tolerability and Pharmacokinetics of Contezolid at Therapeutic and Supratherapeutic Doses in Healthy Chinese Subjects, and Assessment of Contezolid Dosing Regimens Based on Pharmacokinetic/Pharmacodynamic Analysis[J].2019,41(6).
[42]Li, Hanbin,Salinger, David H.,Everitt, Daniel,etc.Long-Term Effects on QT Prolongation of Pretomanid Alone and in Combinations in Patients with Tuberculosis[J].2019,63(10).
[43]Lepak, Alexander J.,Andes, David R..In Vivo Pharmacodynamic Target Assessment of Delafloxacin against Staphylococcus aureus, Streptococcus pneumoniae, and Klebsiella pneumoniae in a Murine Lung Infection Model[J].2016,60(8).
[44]Mushtaq, Shazad,Vickers, Anna,Woodford, Neil,etc.WCK 4234, a novel diazabicyclooctane potentiating carbapenems against Enterobacteriaceae, Pseudomonas and Acinetobacter with class A, C and D β-lactamases[J].2017,72(6).
[45]Marimuthu Jeya,Hee-Jung Moon,Kyoung-Mi Lee,etc.Glycopeptide Antibiotics and their Novel Semi-Synthetic Derivatives[J].2011,12(8).
[46]Anne J,Lenaerts.Preclinical testing of the nitroimidazopyran PA-824 for activity against Mycobacterium tuberculosis in a series of in vitro and in vivo models.[J].2005,49.
[47]Ignacio Martin-Loeches,Glenn E. Dale,Antoni Torres.Murepavadin: a new antibiotic class in the pipeline[J].2018,16(4).
[48]Henrik, Hasman,Anette M, Hammerum,Frank, Hansen,etc.Detection of mcr-1 encoding plasmid-mediated colistin-resistant Escherichia coli isolates from human bloodstream infection and imported chicken meat, Denmark 2015.[J].2015,20.
[49]Chambers, Henry F..Omadacycline - The Newest Tetracycline[J].2019,380(6).
[50]Thomson, Kenneth S.,AbdelGhani, Sameh,Snyder, James W.,etc.Activity of Cefepime-Zidebactam against Multidrug-Resistant (MDR) Gram-Negative Pathogens[J].2019,8(1).
[51]Marty, Francisco M.,Ostrosky-Zeichner, Luis,Cornely, Oliver A.,etc.Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis[J].2016,16(7).
[52]Izabela, Karpiuk,Stefan, Tyski.Looking for new preparations for antibacterial therapy. IV. New antimicrobial agents from the aminoglycoside, macrolide and tetracycline groups in clinical trials.[J].2015,69.
[53]Dur?es, Fernando,Sousa, Emília.Omadacycline: A Newly Approved Antibacterial from the Class of Tetracyclines[J].2019,12(2).
[54]Andrea Novelli,Paola Del Giacomo,Gian Maria Rossolini,etc.Meropenem/vaborbactam: a next generation β-lactam β-lactamase inhibitor combination[J].2020,18(7).
[55]Michael A, Pfaller,Rodrigo E, Mendes,Helio S, Sader,etc.Activity of Dalbavancin Tested against Gram-Positive Clinical Isolates Causing Skin and Skin Structure Infections in Paediatric Patients from US Hospitals (2014 - 2015).[J].2017,(Spec ).
[56]Rimoldi Sara Giordana,Gentile Bernardina,Pagani Cristina,etc.Whole genome sequencing for the molecular characterization of carbapenem-resistant Klebsiella pneumoniae strains isolated at the Italian ASST Fatebenefratelli Sacco Hospital, 2012–2014[J].2017,17(1).
[57]Michalska Katarzyna,Bednarek Elżbieta,Gruba Ewa,etc.Comprehensive spectral identification of key intermediates to the final product of the chiral pool synthesis of radezolid[J].2017,11(1).
[58]William, O'Riordan,Purvi, Mehra,Paul, Manos,etc.A randomized phase 2 study comparing two doses of delafloxacin with tigecycline in adults with complicated skin and skin-structure infections.[J].2015,30.
[59].Meropenem/Vaborbactam, the First Carbapenem/β-Lactamase Inhibitor Combination.[J].2018,(Spec).
[60]Conradie, Francesca,Diacon, Andreas H.,Ngubane, Nosipho,etc.Treatment of Highly Drug-Resistant Pulmonary Tuberculosis[J].2020,382(10).
[61]Izabela, Karpiuk,Stefan, Tyski.Looking for the new preparations for antibacterial therapy. V. New antimicrobial agents from the oxazolidinones groups in clinical trials[J].2017,71(2).
[62]Scott L. J..Delafloxacin: A Review in Acute Bacterial Skin and Skin Structure Infections[J].2020,80(12).
[63]Michael W. Dunne,George H. Talbot,Helen W. Boucher,etc.Safety of Dalbavancin in the Treatment of Skin and Skin Structure Infections: A Pooled Analysis of Randomized, Comparative Studies[J].2015,39(2).
[64]魏海霞,谭薇.治疗医院获得性肺炎新药：murepavadin[J].2019,(2).
[65]Stets, Roman,Popescu, Monica,Gonong, Joven R.,etc.Omadacycline for Community-Acquired Bacterial Pneumonia[J].2019,380(6).
[66]Krisztina M,Papp-Wallace.The latest advances in β-lactam/β-lactamase inhibitor combinations for the treatment of Gram-negative bacterial infections.[J].2019,20(17).
[67]Zhanel George G.,Golden Alyssa R.,Zelenitsky Sheryl,etc.Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli[J].2019,79(3).
[68]周青桐.磷酸泰地唑胺（Tedizolid phosphate）[J].2014,(6).
[69]"ORCID":"http:\/\/orcid.org\/0000-0002-8663-3161Shao-Huan Lan,Shen-Peng Chang,"ORCID":"http:\/\/orcid.org\/0000-0002-6334-2388Chih-Cheng Lai,etc.The Efficacy and Safety of Eravacycline in the Treatment of Complicated Intra-Abdominal Infections: A Systemic Review and Meta-Analysis of Randomized Controlled Trials[J].2019,8(6).
[70]G Ralph, Corey,Jeffery, Loutit,Greg, Moeck,etc.Single Intravenous Dose of Oritavancin for the Treatment of Gram-positive Acute Bacterial Skin and Skin Structure Infections: Summary of Safety from the Phase 3 SOLO studies.[J].2018,(Spec ).
[71]Lamb Yvette N.,Lyseng-Williamson Katherine A..Omadacycline in community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections: a profile of its use[J].2019,35(7).
[72]Lin,G.,Pankuch,G.,Appelbaum,P.C.,etc.Antistaphylococcal activity of oritavancin and its synergistic effect in combination with other antimicrobial agents[J].2014,58(10).
[73]Stover C. Kendall,Warrener Paul,VanDevanter Donald R.,etc.A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis[J].2000,405(6789).
[74]He, Tao,Wang, Ran,Liu, Dejun,etc.Emergence of plasmid-mediated high-level tigecycline resistance genes in animals and humans[J].2019,4(9).
[75]Thu D. M. Pham,Zyta M. Ziora,Mark A. T. Blaskovich.Quinolone antibiotics[J].2019,10(10).
[76]Estes KE,Penzak SR,Calis KA,etc.Pharmacology and antifungal properties of anidulafungin, a new echinocandin.[J].2009,29(1).
[77]Lee HS,Kwak JH,Woo SH,etc.In vitro and in vivo activities of LCB01-0371, a new oxazolidinone.[J].2010,54(12).
[78]Ito, Akinobu,Nishikawa, Toru,Matsumoto, Shuhei,etc.Siderophore Cephalosporin Cefiderocol Utilizes Ferric Iron Transporter Systems for Antibacterial Activity against Pseudomonas aeruginosa[J].2016,60(12).
[79]Mark Arnold Thomas, Blaskovich,Karl A, Hansford,Mark Stuart, Butler,etc.New developments in glycopeptide antibiotics.[J].2018,(Spec ).
[80]Luther Anatol,Urfer Matthias,Zahn Michael,etc.Chimeric peptidomimetic antibiotics against Gram-negative bacteria[J].2019,576(7787).